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Abstract
Introduction As part of a clinical proteomics programme
focused on diabetes and its complications, it was our goal to
investigate the proteome of plasma in order to find improved
candidate biomarkers to predict diabetic nephropathy.
Methods Proteins derived from plasma from a cross-
sectional cohort of 123 type 1 diabetic patients previously
diagnosed as normoalbuminuric, microalbuminuric or mac-
roalbuminuric were enriched with hexapeptide library beads
and subsequently pooled within three groups. Proteins from
the three groups were compared by online liquid chroma-
tography and tandem mass spectrometry in three identical
repetitions using isobaric mass tags (iTRAQ). The results
were further analysed with ingenuity pathway analysis.
Levels of apolipoprotein A1, A2, B, C3, E and J were
analysed and validated by a multiplex immunoassay in 20
type 1 diabetic patients with macroalbuminuria and 10 with
normoalbuminuria.
Results A total of 112 proteins were identified in at least
two out of three replicates. The global protein ratios were
further evaluated by ingenuity pathway analysis, resulting
in the recognition of apolipoprotein A2, B, C3, D and E as
key nodes in the top-rated network. The multiplex
immunoassay confirmed the overall protein expression
patterns observed by the iTRAQ analysis.
Conclusion The candidate biomarkers discovered in this
cross-sectional cohort may turn out to be progression
biomarkers and might have several clinical applications in
the treatment and monitoring of diabetic nephropathy;
however, they need to be confirmed in a longitudinal
cohort.
Keywords Quantitative proteomics . Diabetic
nephropathy . iTRAQ . Protein networks . Pathway
analysis .Multiplex immunoassay technology
Abbreviations
MIC Microalbuminuria
UAER Urinary albumin excretion rate
DMN Diabetic nephropathy
SELDI-TOF-MS Surface-enhanced laser desorption/
ionisation time-of-flight mass
spectrometry
CVD Cardiovascular disease
Apo Apolipoprotein
N Normoalbuminuric
UACR Urinary albumin creatinine ratio
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U-albumin Urinary albumin
GFR Glomerular filtration rate
KW Kruskal–Wallis
IPA Ingenuity pathway analysis
RD Rapid decline
SlD Slow decline
BMI Body mass index
HbA1c Haemoglobin A1c
HCD Higher-energy collision dissociation
CID Collision-induced dissociation
Introduction
Approximately 8% of type 1 diabetic patients develop end-
stage renal disease because of diabetic nephropathy 30 years
after diagnosis [1]. As a consequence, diabetic nephropathy
is the most common cause of renal failure in the developed
world [2, 3]. Diabetic nephropathy advances through a
number of recognisable steps from subclinical disease to
the first measurable stage of microalbuminuria (MIC),
defined as persistent urinary albumin excretion rates
(UAER) of 30–300 mg/24 h, to macroalbuminuria/diabetic
nephropathy (DMN) with UAER > 300 mg/24 h. DMN is
characterised by declining renal function and ultimately
end-stage renal disease. Although positive effects on the
development and progression of diabetic nephropathy
through strict control of blood glucose [4], blood pressure
[5] and, in particular, blockade of the renin–angiotensin
system (6, 7) have been reported, it still has not been
enough to prevent the high incidence of end-stage kidney
damage caused by diabetes. The urinary albumin excretion
rate is used to identify patients at risk, but only a fraction of
all patients with microalbuminuria progress to DMN. New
biomarkers that can help in identifying normo- or micro-
albuminuric patients at risk for progression to DMN are
needed as early intervention could further curb progression
to DMN and end-stage renal disease.
Access to plasma samples from a cross-sectional study at
the Steno Diabetes Center of type 1 diabetic patients with
various degrees of diabetic nephropathy formed the basis
for this study. The same cohort was previously investigated
by fractionation coupled with surface-enhanced laser
desorption/ionisation time-of-flight MS (SELDI-TOF-MS),
which resulted in the discovery of differential levels of
apolipoprotein C1 and apolipoprotein A1 along with trans-
thyretin and cystatin C [8].
In this study, the cohort was further analysed using
iTRAQ labelling (Applied Biosystems Inc.) and LC-MS/
MS. In order to identify low abundant proteins in the
plasma, we subjected the samples to hexapeptide library
bead-based fractionation before proteolysis, iTRAQ label-
ling and LC-MS/MS. The hexapeptide library beads have
been reported to have the capacity to reduce the most
abundant proteins in plasma whilst simultaneously concen-
trating the most dilute species [9]. The library contains
linear hexapeptides with millions of different ligands. The
diversity and number of peptides should result in specific
baits for a large number of proteins present in a complex
proteome [10, 11]. Because the library has the same
quantity of each ligand, hypothetically, the maximum
amount of each protein bound is the same under over-
loading conditions [12, 13]. The iTRAQ labelling simpli-
fied the analysis and included protein identification
information not present in previous studies. Evaluation of
the iTRAQ results by ingenuity pathway analysis identified
apolipoproteins A2, B, C3, D and E as central nodes in a
network that was highly rated. For that reason, the
apolipoprotein profile of type 1 diabetic patients were
investigated further in a cohort of patient samples that were
chosen based on the rate of loss of kidney function over a
time period of 4 years. We compared the ten patients with
the fastest rate of decline with those with the slowest rate of
decline. Ten samples came from patients with DMN and a
high loss of renal filtration based on the measurement of
GFR (annual difference in ΔGFR > 5.2 ml min−1/1.73 m2,
termed RD), and ten samples came from DMN patients with
a relatively slow decline of renal filtration, ΔGFR < 3.3
(termed SlD). In addition, ten samples from normoalbumi-
nuric patients were analysed. The samples were analysed by
the cardiovascular disease (CVD) immunoplex assay from
Merck (Whitehouse Station, NJ, USA) detecting apolipopro-
tein A1, A2, B, C3, E, H and J.
By exploring the plasma proteome using a different
approach, we aimed to expand our list of candidate
biomarkers for diabetic nephropathy. Biomarkers identify-
ing MIC or DMN in this cross-sectional study can be
evaluated as potential predictors of the development of
diabetic nephropathy in longitudinal studies of diabetic
patients.
Materials and Methods
Patient Cohort
The cohort was collected as a part of the GENEX Study in
2004 [14, 15], and a total of 123 samples from Caucasian
type 1 diabetic patients examined and diagnosed at Steno
Diabetes Center had the adequate volume for the MS
analysis. The patients were divided into three groups,
normoalbuminuric (N, n=42), MIC (n=40) and DMN
(n=41), according to the UACR in at least two out of three
consecutive urines collected in the outpatient clinic. The
time between DMN diagnosis and sample collection for the
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GENEX cohort was variable. DMN patients were selected
for the presence of DMN irrespective of its duration. All
patients in the DMN group, except for three, were being
treated to reduce their blood pressure, and consequently,
their urinary albumin (U-albumin) at the time of the blood
sample collection was not necessarily representative of the
stage of the disease. At the time of plasma sampling, 26 out
of 41 DMN patients still had high U-albumin levels, whilst
13 had intermediate levels and two had levels low enough
to place them in the N group. Of the 15 patients whose
levels were lower than at the point of diagnosis, five were
put on a short break from their antihypertensive medication
and three of them returned to DMN levels before
continuing their medication. The two other patients had
significant level increases of DMN values and support the
original diagnosis. In a follow-up period 4 years after
sampling, there were only three patients (two from MIC
and one from N) who had progressed to diabetic nephrop-
athy. The low progression rate may be explained by the
stable disease state of this cohort at baseline without
diabetic nephropathy despite long-standing diabetes.
The three diabetic groups were matched at group level
by gender, age and duration of diabetes. Investigations and
blood sampling were performed in the morning after an
overnight fast and has been thoroughly described previous-
ly [8]. Comparisons of clinical data between the three
groups were made with Prism 5 software (GraphPad
Software, CA, USA). Values of p were two-sided, and a
p value <0.05 was considered statistically significant. The
Kruskal–Wallis (KW) test was used for ordinal data
(gender). The distributions of continuous data were tested
for normality by the D’Agostino–Pearson omnibus normal-
ity test. If distributions were normal, data were compared
with one-way ANOVA, and if distributions were not
normal, data were compared with a KW test.
The study was approved by the local ethics committee
and all patients gave their informed consent.
Protein Purification and iTRAQ Sample Labelling
Patient plasma was fractioned with ProteoMiner beads as
described previously [8]. Plasma proteins within each group
were pooled and 100 μg protein was aliquoted three times
for triplicate studies. Each replicate was precipitated with
six times the volume of cold acetone separately, yielding a
total of nine individual samples. The samples were reduced
and blocked as suggested by the manufacturers. Proteins
were digested overnight with Trypsin (2%, w/w), and the
resulting peptides were subsequently labelled using iTRAQ
4-plex. The three samples from the DMN group were
labelled with iTRAQ 114, the MIC group samples iTRAQ
115 and the N group samples iTRAQ 116, and dried in a
vacuum centrifuge. The samples were reconstituted in
500 μL SCX loading buffer (Applied Biosystems) and
mixed 1:1:1 to give a final of three mixed samples (each
containing one iTRAQ 114-labelled DMN sample, one 115
iTRAQ-labelled MIC sample and so forth). The pH of the
samples was adjusted to 2.5–3 with HCl and fractioned on a
SCX column with 50, 100, 150, 200, 250, 300, 350, 400,
500 mM and 1 M KCl. The pH values of the fractions were
adjusted to 2–3 and cleaned on C18 Stagetips (Proxeon,
Odense, Denmark) using 50 μL 100% ACN as wetting
solution, 50 μL 0.1% TFA for equilibrating the tips and
washing the sample after loading, and, finally, elution of the
peptides with 50 μL 0.1% TFA and 50% ACN. Afterwards,
the samples were completely dried.
Nano-liquid Chromatography Tandem Mass Spectrometry
Peptides from the SCX fractions were dissolved in 0.3 μL
100% formic acid and diluted to 5 μL in 0.05% TFA. The
peptides were loaded onto an EASY-nano LC system
(Proxeon). Peptides were loaded directly onto a 20-cm,
100-μm inner diameter and 360-μm outer diameter,
ReproSil-Pur C18 AQ 3 μm (Dr. Maisch, Ammerbuch-
Entringen, Germany) reversed phase capillary column. The
peptides were eluted using a gradient from 100% phase A
(0.1% formic acid) to 40% phase B (0.1% formic acid, 80%
acetonitrile) over 100 min at 200 nL/min directly into a
LTQ-Orbitrap XL mass spectrometer (Thermo Scientific,
San Jose, CA, USA). The LTQ-Orbitrap XL was operated
in a data-independent mode automatically switching be-
tween MS, MS/MS and higher-energy collision dissociation
(HCD) using a threshold of 30,000 for ion selection. For
each MS scan, the two most abundant precursor ions were
selected for fragmentation using MS/MS (normalised
collision energy, 35; activation time, 30 ms) to facilitate
peptide identification and then subsequently HCD (normal-
ised collision energy, 55) to obtain reliable iTRAQ
quantitative data [16]. Raw data were viewed in Xcalibur
v2.1 (Thermo Scientific).
Data Processing and Protein Sequence Database Searching
The data were processed using Proteome Discoverer,
version 1.1.0.228. The files were subsequently submitted
to an in-house MASCOT server (version 2.2.05, Matrix
Science Ltd., London, UK) for database searching through
the Proteome Discoverer programme. The data were
searched against the human sequence database (NCBInr
20100602 (11186807 sequences; 3815639892 residues);
taxonomy: Homo sapiens (human, 232199 sequences)).
The search was performed choosing trypsin as specific
enzyme. A maximum of one missed cleavage was allowed.
Oxidation (M), iTRAQ 4plex (K) and iTRAQ 4plex
(N-term) were chosen as variable modifications. The data
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obtained on the LTQ-orbitrap XL were searched with a
peptide mass tolerance of 10 ppm and a fragment mass
tolerance of 0.8 Da. Protein ratios were normalised using
the overall median ratio for all the peptides in the sample
for each separate ratio in every individual experiment. The
ratio for a given protein was calculated by taking the
average of all the peptides ratios that identified the protein.
The final list of protein ratios was an average of the protein
ratios of the three experiments and consisted only of
proteins discovered in at least two of the three experiments.
Ingenuity Pathway Analysis
The iTRAQ results were evaluated using ingenuity pathway
analysis (IPA; Ingenuity Systems, Mountain View, CA;
www.ingenuity.com). This software analyses protein ex-
pression data in the context of known biological response
and regulatory networks as well as other higher-order
response pathways. IPA constructs hypothetical protein
interaction clusters on the foundation of a regularly updated
Ingenuity Pathways Knowledge Base, which is a very large
database that consists of millions of individual relationships
between proteins gathered from the biologic literature [17].
The data set that contained the differentially expressed
proteins identified in the iTRAQ experiment was converted
by IPA to ‘fold change’ and uploaded into IPA. No
expression value cutoff was selected, and we were
interested in looking at both up- and downregulated
proteins. Hypothetical networks were generated from these
proteins and other proteins from the database that were
needed to fill out a protein cluster. Network generation was
optimised for the inclusion of as many proteins from the
input expression profile as possible and aimed for highly
connected networks.
IPA computes a score for each possible network
according to the fit of that network to the input proteins.
The score is calculated as the negative base-10 logarithm of
the p value that indicates the probability of the input
proteins in a given network being found together as a result
of random chance. Consequently, scores of 2 or higher have
at least a 99% confidence of not being generated by random
chance alone [17].
Bioplex Assay
Concentrations of Apo A1, A2, B, C3, E, H and J were
simultaneously evaluated using a multiplex bead-based
sandwich immunoassay kits (Novagen WideScreen ™
Human CVD Panel 1, Merck Chemicals Ltd. Nottingham,
UK). Assays were performed following the manufacturer’s
instructions. Briefly, seven distinct sets of fluorescently
dyed beads loaded with capture monoclonal antibodies
specific for each apolipoprotein to be tested were used.
Plasma samples diluted 1:2,500 with dilution buffer
(30 μL/well) or standards (30 μL/well) along with 10 μL
of biotinylated antigens in blocking buffer were incubated
with 10 μl of pre-mixed bead sets into the wells of a pre-
wet 96-well microtitre plate. After incubation and washing,
20 μL of fluorescent detection antibody mixture (Streptavidin
PE) was added for 30 min and the samples were washed and
resuspended in assay buffer. The formation of different
sandwich immunocomplexes on distinct bead sets was
measured and quantified using the Bio-Plex Protein Array
System (Bio-Rad Laboratories). A 50 μL volume was
sampled from each well and the fluorescent signal of a
minimum of 100 beads per region (chemokine/apolipopro-
tein) was evaluated and recorded. Values presenting a
coefficient of variation beyond 15% were discarded before
the final data analysis.
Data Analysis and Statistics
The clinical data were evaluated by the Prism software. Bio-
plex data were analysed using the Bio-Plex Manager software
version 3.0 (Bio-Rad Laboratories). Standard levels between
80% and 120% of the expected values were considered to be
accurate and were used. Values were expressed as nanograms
per millilitre and presented as mean (SD).
Results
Clinical Data
The clinical data of the GENEX cohort are summarised in
Table 1. Patient groups in the cross-sectional cohort were
matched with respect to gender, duration of diabetes and
body mass index (BMI), but differed slightly by age
(p=0.01). The DMN group had significantly lower esti-
mated glomerular filtration rates (eGFR) compared to the
other groups (p<0.0001), whilst equivalent eGFR values
were observed in the N and MIC groups. There were no
significant differences in systolic blood pressure or diastolic
blood pressure for comparisons of all groups or for levels of
serum cholesterol between the groups. Haemoglobin A1c
(HbA1c) differed significantly for an all group comparison
(p=0.02); this was caused by a significant difference
between the N and DMN groups.
Quantitative Comparison of the Three Patient Samples
Protein identifications were initially accepted when based
on peptide identifications with Mascot scores of ≥25 and a
false discovery rate of <1%. This resulted in the identifi-
cation of 3,365, 3,667 and 3,495 peptides, respectively,
from the iTRAQ triplicate experiments. In total, 130, 133
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and 122 proteins were identified in experiments 1, 2 and 3,
respectively. The relative quantitation was measured as two
pairwise ratios: the MIC group against the DMN group
(iTRAQ115/iTRAQ114) and the N group against the DMN
group (iTRAQ116/iTRAQ114). A total of 112 proteins
were identified in at least two out of three iTRAQ runs. The
molecular identity and abundance ratios of the 112 proteins
are listed in Electronic Supplementary Materials. Examples
of MS/MS spectra of peptides from apo E and A1 are
presented in Fig. 1.
Ingenuity Pathway Analysis
Figures 2 and 3a shows one of the largest protein clusters
that were generated by the pathway analysis of the protein
ratios between N/DMN. This network consists of a cluster
of 35 proteins, of which 15 were not included in our list.
The network was suggested to be involved in cardiovascu-
lar disease, genetic disorders and metabolic diseases, and
had a score of 36. Apo A2, B, C3, D and E were all
included in this protein network, and the results inspired us
to look further into these apolipoproteins in plasma.
Multiplex Immunoassay Results
For further analysis of the aforementioned apolipoproteins
and validation of the iTRAQ results, 30 plasma samples
were selected for quantitative measurements of apolipopro-
teins by a multiplex immunoassay. The patient samples
were chosen based on the rate of loss of kidney function
over a time period of 4 years. Ten samples came from
patients with DMN and a high loss of renal filtration based
on the measurement of GFR (annual difference in ΔGFR >
5.2, termed RD), and ten samples came from DMN patients
with a relatively slow decline of renal filtration, ΔGFR <
3.3 (termed SlD). In addition, ten samples from normoal-
buminuric patients were analysed.
The clinical data for the 30 patients chosen for the
multiplex immunoassay is listed in Table 2.
There was no significant difference in GFR measured in
2004 between the RD and SlD groups. The distribution of
gender, systolic and diastolic blood pressure, BMI, HbA1c,
cholesterol and triglyceride values were not significant
different across all three groups. The RD and SlD groups
varied in the decline of renal function (ΔGFR) over a
subsequent 4-year period (p=0.0002). At follow-up, the
three groups varied slightly in age and duration of diabetes.
This was caused by one young patient (aged 27) in the RD
group and one patient with only 2 years of diabetes also in
the RD group.
Plasma concentrations of apo A1, A2, B, C3, E, H and J
were detected in all the patients. Table 3 shows the
concentrations of the measured apolipoproteins in the N,
SlD and RD groups. The concentrations of the apolipopro-
Table 1 Clinical data of the GENEX cohort differentiated according to the level of albuminuria
N MIC DMN p value
n, total 42 40 41
Gender, male/female 19/23 18/22 22/19 0.25
Age (years) 56 (11) 55 (11) 49 (10)a 0.01b
DM duration (years) 36 (11) 36 (11) 34 (10) 0.58
BMI (kg/m²) 24.5 (2.8) 25.2 (3.7) 25.3 (4.5) 0.62
HbA1c (%) 8.2 (1) 8.8 (1.2) 8.9 (1.1)a 0.02*
Creatinine (μmol/l)b 91 (82–96) 90 (81–102) 124 (99–172)a,c <0.0001*
U-albumin (mg/g)b,d 6 (4–8) 23 (9–59) 453 (195–936)a,c <0.0001*
eGFR (mlmin−1/1.73 m²) 70.1 (10.7) 68.6 (11.4) 49.5 (18.5)a,c <0.0001*
Cholesterol (mmol/l) 4.8 (0.8) 5 (1) 4.9 (1) 0.55
Systolic BP (mmHg) 138 (23) 140 (23) 144 (19) 0.42
Diastolic BP (mmHg) 74 (10) 73 (12) 78 (10) 0.09
Numbers are presented as mean (SD)
n numbers, DM diabetes mellitus, HbA1c haemoglobin A1c, U-albumin urinary albumin levels normalised to creatinine levels, eGFR estimated
glomerular filtration rate, BP blood pressure
*p<0.05
a Indicates that means differed significantly between DMN group and N group
b Numbers are presented as median (IQR 25%–75%)
c Indicates that means differed significantly between DMN group and MIC group
d Some patients had U-albumin levels reduced by antihypertensive medication which was not stopped when spot urine samples were collected for the study
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teins did not differ between the three groups. Apo A1
concentrations correlated with systolic blood pressure
(Spearman ρ coefficient = −0.45, p=0.014), Apo A2 with
triglycerides (Spearman ρ coefficient = 0.41, p=0.0245),
Apo B with age (Spearman ρ coefficient = 0.3642,
p=0.0478) and Apo C3 with cholesterol (Spearman
ρ coefficient = 0.4361, p=0.0160). There was no correla-
tion between ΔGFR and concentrations of apolipoproteins
in the SlD and RD groups, nor any between the GFR in
2004 and apolipoproteins in all three groups.
In order to compare the concentrations of the apolipo-
proteins from the multiplex immunoassay with the ratios
of the apolipoproteins from the iTRAQ experiment, the
average of the specified protein from the N group was
divided by the average of the two macroalbuminuric
(N/SlD + RD) groups and the SlD (N/SlD) and RD
(N/RD) groups separately (Fig. 4). The ratios of the
apolipoprotein in the multiplex immunoassay had, overall,
the same pattern as first revealed by the iTRAQ analysis,
except for apo C3 and apo J where the reversed
relationship was seen between iTRAQ and the multiplex
immunoassay.
Discussion
Identification of biomarkers in the blood of patients with
high risk of developing diabetic nephropathy may have
several clinical applications, including more aggressive
control of glucose or arterial blood pressure, earlier onset
of renoprotective treatment and a more tailored manage-
ment of the disease.
Although several studies of urine, plasma and serum
from T2D patients have been conducted [18–21], the
plasma of T1D patients has not been fully examined. In
this report, we present data to show that plasma obtained
from three different stages of diabetic nephropathy in
T1D patients contains candidate biomarkers for diabetic
nephropathy.
Plasma samples from a cross-sectional study conducted
at Steno Diabetes Center in 2004 formed the foundation of
the investigations presented here. Previously, the plasma
samples were fractioned with ProteoMiner beads and
analysed on SELDI-TOF-MS [8]. The SELDI-TOF-MS
approach relied on a side-by-side comparison of spectra
generated from each patient and revealed a number of
protein peaks significantly different between patients
divided into groups according to albuminuria. The disad-
vantage of this methodology was the time-consuming job
of identifying the various protein peaks in the spectra by
immunoprecipitation, sequencing and Western blots. The
combination of isobaric labelling using iTRAQ and LC-
MS/MS offered a way to overcome this situation. Peptides
are identified in the MS/MS mode, whilst quantitation is
obtained from the iTRAQ reporter ion using higher-energy
collision dissociation (HCD) and collision-induced dissoci-
ation (CID). A total of 112 proteins were identified in at
least two out of three repetitions of the experiments. The
protein number is relatively low compared to other
published studies, such as those reported for a head and
Fig. 1 a MS/MS spectrum
of the C-terminal peptide from
apolipoprotein E (sequence
QAAVGTSAAPVPSDNH). The
assignment of the peptide is
illustrated by the y- and b-ions
in the spectrum. b MS/MS
spectrum of the peptide with the
sequence LLDNWDSVTSTFSK
from apolipoprotein A1
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neck cancer biomarker discovery study and protein expres-
sion profiling of plasma from patients with placental
diseases where 811 and 166 proteins were identified,
respectively [22, 23]. An explanation could be the initial
treatment with ProteoMiner beads; previously, Pernemalm
et al. [24] evaluated the ProteoMiner technique on crude
plasma and identified only 150 unique proteins by direct
LC-MS/MS and GeLC-MS/MS with a start plasma volume
Fig. 2 Top-rated network
generated by ingenuity pathway
analysis on the N/DMN ratio.
Red nodes indicate that the
protein is upregulated in the
DMN group compared to
the N group. Stronger red
colours indicate higher
regulation of the complex
RD SlD N p value
n, total 10 10 10
GFR 2004a (mL/min) 60.76 (11.3) 54.7 (7.9) – 0.1051
ΔGFRa (mL/min) over 4 years 6.61 (1) 2.17 (1.6) – 0.0002*
Age (years) 42.20 (8.3) 52.50 (9.2) 57.90(11.7) 0.0062*
Gender, %male 50 50 20 0.2987
Diabetes duration (years)a 27.90 (11.5) 37.10 (6) 41.40 (10.3) 0.017*
Systolic BP (mmHg) 137.4 (18.8) 133.0 (26.3) 138.1 (18.9) 0.9757
Diastolic BP (mmHg) 76.70 (9.5) 69.40 (16) 76.30 (11.4) 0.3859
BMI (kg/m2) 25.86 (4.2) 26.31 (6.5) 24.01 (1.7) 0.5544
HbA1C (%) 8.680 (1) 8.480 (1) 7.770 (0.8) 0.0822
Cholesterol (mmol/L) 4.660 (0.6) 4.920 (0.8) 5.030 (5) 0.5188
Triglycerides (mmol/L) 1.132 (0.4) 1.067 (0.3) 0.9870 (0.5) 0.5569
Table 2 Clinical data
for patients chosen for the
multiplex immunoassay
Numbers are presented as mean
(SD)
n numbers, eGFR estimated
glomerular filtration rate,
BP blood pressure, HbA1c
haemoglobin A1c
*p<0.05
a Non-parametric data were evalu-
ated by a Kruskal–Wallis F test or
a Mann–Whitney test when only
two values were compared
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comparable to ours. Additionally, a recent study demon-
strated that iTRAQ isobaric tags significantly increased the
average ion charge state of peptides, resulting in a
considerable reduction in the number of peptides identified
from a given sample when using CID and HCD peptide
fragmentation [25].
Some of the more interesting proteins identified in this
study are the lipoproteins where the majority are present in
higher levels in MIC and N compared to DMN. Evaluation
of the iTRAQ data by ingenuity pathway analysis identified
apo A1, A2, B, C3, E and J (Clusterin) to contribute in the
top-rated network (Fig. 2). Diabetes has been shown to be
Table 3 Concentrations of Apo A1, A2, B, C3, E, H and J in the plasma of the diabetic patients divided by GFR
RD SlD N p value
Apo A1 (ng/mL) 4.289e+006 (1.752e+006) 4.653e+006 (1.715e+006) 4.925e+006 (2.021e+006) 0.7427
Apo A2 (ng/mL) 184,582 (47,323) 237,641 (177,992) 167,090 (66,080) 0.7145
Apo B (ng/mL) 1.528e+006 (137,227) 1.486e+006 (104,370) 1.537e+006 (100,729) 0.5790
Apo C3 (ng/mL) 66,449 (20,720) 73,448 (48,535) 56,741 (29,542) 0.6600
Apo E (ng/mL) 32,008 (14,590) 38,629 (9,400) 37,414 (7,629) 0.3682
Apo H (ng/mL) 164,944 (32,147) 182,433 (95,217) 129,301 (46,866) 0.1048
Apo J (ng/mL) 137,605 (17,021) 139,465 (29,007) 136,150 (22,101) 0.9502
Numbers are presented as mean (SD)
Fig. 3 a Network shapes.
Figure legend for the IPA
network. https://analysis.
ingenuity.com/pa/info/help/help.
htm#legend.htm. b Relation-
ships. Figure legend for the
molecular relationships in the
IPA network. https://analysis.
ingenuity.com/pa/info/help/help.
htm#legend.htm
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associated with the amounts of different classes of
apolipoproteins, and accordingly, the apolipoproteins might
contribute to the development of diabetic nephropathy and
cardiovascular disease [26]. Apo B, Apo C1 and C3 are
according to Hirano et al. [27] increased in patients with
diabetic nephropathy compared to healthy individuals. We
observed the same tendency in our results for apo C3 where
higher levels of this protein were found in the groups with
macroalbumninuria. Several reports have investigated dif-
ferent isoforms of apo E caused by three different alleles of
the gene coding for apo E [28–30], and it has been
suggested that the apo E4 isoform protects against diabetic
nephropathy whilst the apo E2 isoform promotes the
disease [31, 32]. We did not see any differences in the
overall level of apo E in the different patient groups,
suggesting that diagnostic potential of the protein poten-
tially should be found in the different isoforms in contrast
to the generally protein level. Apo A1 levels were lower in
patients with macroalbuminuria in our study, although not
statistically significant. Tolonen et al. [33] reported that low
apo A1 levels predicted the progression of patients with
macroalbuminuria to end-stage renal disease, and it might
be reasonable to speculate that low levels of this protein in
some way is associated to the development and progression
of diabetic nephropathy. Whether the abnormal levels of the
apolipoproteins are causing the development of diabetic
nephropathy and therefore could be used as potential
predictive markers or are just a consequence of the disease
is difficult to say based on these cross-sectional studies
presented here. The issue would ideally be addressed
through further investigation in a longitudinal study.
To verify our results obtained with the iTRAQ investi-
gation and ingenuity pathway analysis, we examined apo
A1, A2, C3, E, H and J on an orthogonal platform in a
series of patients with macroalbuminuria that had either a
fast decline in kidney function (GFR, the RD group) and
patients with macroalbuminuria and a slower decline in
GFR (the SlD group) over 4 years. The ratios obtained in
the iTRAQ analysis and the multiplex immuno-analysis
appear quite similar. Differences could be explained by the
initial treatment with ProteoMiner beads of the samples for
the iTRAQ experiment, whereas the multiplex immunoas-
say was conducted on untreated plasma. Another explana-
tion could be the difference in the number of plasma
samples that constitutes the pool, i.e. the fact that the
iTRAQ analysis is conducted in pools of plasma samples
from a larger group of patients and therefore individuals
with very high or low levels of protein would be diluted. In
the multiplex immunoassay experiment, one patient had
very high levels of apo A1, A2, C3 and H, and this resulted
in a general higher average of these proteins. Another
explanation could be potentially different isoforms of the
apolipoproteins, with differences in which isoforms can be
detected by the method employed. A recent paper by
Borges et al. [34] reviews the microheterogenity of the
human proteome. Evidently, polymorphisms, transcript
variants and posttranslational modifications give rise to
structurally similar but functionally distinct proteins whose
detection is platform-dependent.
Originally, we hypothesised that apolipoprotein levels
would be different between patients with macroalbuminuria
that had a fast decline in kidney function (GFR, the RD
group) and patients with macroalbuminuria and a lower fall
in GFR (the SlD group). This was not observed in this
study, possibly because of the relatively low number of
samples in each group.
The candidate biomarkers discovered in this cross-
sectional cohort may turn out to be progression biomarkers,
but they need to be confirmed in a longitudinal cohort. The
patients in the cohort all represent a stable disease state due
to their long duration, and the proteins discovered in this
study are indeed indicative of their current state, but
temporal information about the changes needs to be
investigated. The nature of the current cohort with a spread
in U-albumin in the DMN and MIC group brings
robustness and persistence to the actually obtained candi-
date biomarkers and reflects everyday clinical setting.
In this study, we investigated the plasma protein
profiles from T1D patients with various degrees of
albuminuria using hexapeptide library fractionation,
iTRAQ labelling and LC-MS/MS, with the result of
increasing our list of candidate biomarkers for diabetic
nephropathy. Future research is aimed at analysing larger
groups of samples. After establishing a model based on
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proteomic patterns for the separation of the three groups,
the model will be validated in longitudinal sample sets to
determine the diagnostic and predictive value of the obtained
protein profiles. It is our goal to discover biomarkers able to
predict, detect and monitor the progression of DMN and the
effect of reno-protective intervention in diabetic patients.
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